Forty patients with lymphoid malignancies were studied. They were autografted with peripheral blood progenitor The efficacy of growth factor administration to accelerate cells (PBPC) during the period between February 1993 and hemopoietic reconstitution following autologous bone marJanuary 1996; the first 20 patients (control group) had no row (BM) transplantation is well established. [1] [2] [3] [4] [5] [6] [7] Less hemopoietic support after PBPC autograft, whereas the foldefinitive data are available on the role of growth factors lowing 20 patients (G-CSF group) received G-CSF following autograft with mobilized peripheral blood pro-(Filgrastim; Amgen, Thousand Oaks, CA, USA). All genitor cells (PBPC). Contradictory results have been patients gave informed consent according to Institution reported so far, concerning both acceleration of neutrophil rules. Patients in either group were selected by the followrecovery and overall clinical benefit. [8] [9] [10] [11] [12] [13] [14] [15] So, growth factor ing criteria: (1) matched clinical characteristics; (2) identadministration after PBPC autograft is not widely accepted.
ical conditioning regimen; (3) autograft performed with comparable amounts of PBPC, without additional marrow cells. The main clinical features of the patients are shown
Correspondence: Dr C Tarella, Cattedra di Ematologia, Via Genova 3, in Table 1 . There was slight, not statistically significant 10126 Torino, Italy Received 20 July 1997; accepted 1 October 1997 (P = 0.28) difference in the median age between the two 402  Table 1 Main characteristics of the two groups of patients receiving
Collection and evaluation of hemopoietic progenitors
or not receiving G-CSF after autograft and quantity of peripheral blood PBPC were mobilized and collected after HD-CY in 36
progenitors reinfused patients, after HD-VP16 in the remaining four patients (one
G-CSF group Control group
of the G-CSF group and three of the control group). To predict the number and timing of leukaphereses, circulating
No. of patients 20 20 CD34+ve cells along with cell blood counts were evaluated Age (years) (median, range) 37 45 daily starting from day +9 following chemotherapy admin- granulocyte-macrophage (CFU-GM). The CFU-GM colony assay was performed by plating in semisolid-medium groups; also a marginally significant difference (P = 0.052) 1, 10 and 100 l of the buffy coat obtained from leukapherin sex ratio was present, with a prevalence of male patients esis cell suspension without any additional cell separation, in the control group. Most patients had non-Hodgkin's lymas described elsewhere. 27, 30 The total number of CD34+ve phoma, with low-grade (four and seven in G-CSF and concells (×10 6 /kg) and CFU-GM (×10 4 /kg) collected was trol groups, respectively) or intermediate high-grade (12 determined by multiplying their frequency per ml by the and eight in G-CSF and control groups, respectively) histotal volume of cryopreserved cell suspension and dividing tology, or Hodgkin's disease (three for either group). In by body weight. Values of 30 × 10 4 CFU-GM/kg and spite of these minor differences, the two groups were well 5 × 10 6 CD34+ve cells/kg were taken as the minimal matched, since patients at diagnosis were equal in number required dose to enroll patients in autografting programs and patients with recurrent disease were all at first relapse with PBPC only. With only two exceptions, all patients and had received comparable first-line treatments. In were autografted with PBPC amounts higher than 50 × 10 4 addition, they were autografted with overimposable quan-CFU-GM/kg and 8 × 10 6 CD34+ve cells/kg (see Table 1 ). tities of PBPC (see Table 1 ).
A median of two leukaphereses (range 1-4) were required to collect enough PBPC for autograft. Whenever possible, Treatment plan an extra collection was performed after having reached the amount of 5 × 10 6 CD34+ve cells/kg in order to keep All patients were part of study protocols based on the use some spare. of the original or modified high-dose sequential (HDS) chemotherapy regimen. 23 ) and HD-etopoevery 2 h on day −2; PBPC were reinfused 2 days later. side (VP16) (2 g/m 2 ); G-CSF was daily administered at The first 20 patients were autografted in the period Febru-5 g/kg following both CY and VP16, to reduce hematolary 1993 to November 1994 and did not receive any growth ogical toxicity and to expand the circulating hemopoietic factor support to accelerate engraftment; the following 20 progenitor cell pool. HDS regimen is completed by a final patients (December 1994 to January 1996) received submyeloablative treatment followed by autograft of PBPC 5 g/kg/day of G-CSF i.v. over 1 h starting on day +1 until harvested after either CY or VP16. The modified HDS the neutrophil count reached 500/l on 2 consecutive days. includes: (1) a prolonged debulking phase with one to two APO courses and/or one to two DHAP courses; 26 (2) inversion of the sequence CY → VP16; (3) inclusion of a Supportive care chemotherapy-free interval before the final HD-CY in order to allow recovery of marrow functions and optimal progeniThe entire pre-transplant program was carried out in ordinary, non-protected rooms; for the autograft phase all tor cell mobilization. 27 Details about original or modified HDS regimens have been previously reported. 23, 24, 28 patients were admitted to a dedicated inpatient bone mar-row transplant unit. Typically, the patients received the regular ward; the cost for staying in the protected environment of our Transplant Unit was calculated at approxiconditioning regimen in the ordinary ward and were subsequently transferred to the protected area by day 0. During mately US$1050 per day. Finally, the price of 1 U of platelet (Plt) transfusion from single donor and of 1 U of red the recovery phase following autograft patients were managed with a common protocol for prophylaxis and therapy blood cells (RBC) is US$548 and 203, respectively. of pancytopenia-related complications. Briefly, antibiotic prophylaxis included oral ciprofloxacin (500 mg twice a Statistical analysis day) + fluconazole (150 mg) + i.v. acyclovir (250 mg three times a day); in case of fever Ͼ38°C, blood culture and Primary end points were hematological recovery and clinichest X-ray were performed, then patients were empirically cal outcome parameters, including: (1) duration of fever; treated with i.v. mezlocillin + amikacin + vancomicin; if (2) incidence and duration of infectious complications; (3) the fever was of undetermined origin and persisted after duration of non-prophylactic antibiotic therapy; (4) time to 36-48 h, mezlocillin was replaced by imipenem; i.v.
hospital discharge. The secondary endpoint was the treatamphotericin was added in few cases with fever persisting ment cost. Differences in the means of continuous measurefor 36-48 more hours. Antibiotics were continued until the ments were compared in the two groups of patients by the temperature reverted to normal values for at least 2 conMann-Whitney U test for unpaired data. The criterion for secutive days along with the return of the ANC to Ͼ500/l. statistical significance was defined as a P value of Ͻ0.05. Parenteral antibiotics were also started in the absence of
All P values presented are two-sided. The proportions of fever whenever patients were unable to continue oral patients with a given characteristic were compared by the prophylactic antibiotics, due to mucositis. Irradiated, leukoFisher's exact test. The log-rank test was applied to evalucyte-filtered, single-donor or, less frequently, multipleate statistical differences in the Kaplan-Meier plot of ANC donor platelet concentrates were given when platelet count recovery to Ͼ500l. was less than 20 000/l; irradiated, leukocyte-filtered packed RBCs were given if hemoglobin was less than 8.0 g/dl.
Results
Post-graft hemopoietic recovery Cost analysis
Postgraft hemopoietic recovery data are shown in Figure 1 There were no differences in treatment costs between the and Table 2 . Administration of G-CSF significantly accelertwo study groups regarding PBPC collection, conditioning ated neutrophil recovery and the median time to regimen and pre-graft hospitalization. Differences in costs ANC Ͼ500 and 1000/l was 4 and 6 days shorter in the were investigated for the post-graft recovery period until G-CSF-treated patients compared to controls (P Ͻ 0.0001). hospital discharge. Beside the daily cost of G-CSF adminisThe faster ANC recovery in patients receiving G-CSF comtration, the following costs were considered: antibiotics, pared to controls can be best seen in Figure 2 , showing it as parenteral nutrition, blood products, laboratory services, a Kaplan-Meier plot. There were no significant differences days spent in hospital. Since the trial did not prospectively between the two groups in the duration of thrombocytopcollect economic data, financial data from the Departmental enia as well as in transfusion requirements (see Tables 2  Bone Marrow Transplantation Unit were used to estimate  and 3) . However, a trend towards a faster platelet reconstidifferences in treatment costs between the two study tution was observed among G-CSF-treated patients. No groups. All patients undergoing autograft at our center have patients had graft failure; indeed, cell blood counts at 3 been managed according to well-defined, homogeneous and 6 months after autograft were consistent with stable protocols for supportive care; also, guidelines for the use engraftment, without major differences between the two of parental antibiotics were the same; finally, all patients groups (data not shown). are daily monitored for routine blood tests and they have more extensive laboratory analysis (complete biochemical profile + clotting tests + microbiological monitoring) twice
Other outcome parameters a week. The total cost for antibiotics, parenteral nutrition and routine laboratory tests was evaluated in 114 patients Autografting was relatively well tolerated in both groups, without severe infectious complications and no toxic autografted in 1994 and 1995; unit prices were determined by calculating the total expense divided by the number of deaths. Mucositis of grade II-III was the most frequent complication, occurring in 14 and 19 patients of G-CSF patients; this value was then divided by the calculated median period under antibiotics, parenteral nutrition or rouand control groups, respectively. As shown in Table 3 , incidence and severity of mucositis were reduced among Gtine laboratory diagnostic monitoring to obtain the price per day for each of these activities. Costs were calculated CSF-treated patients, compared to controls, as suggested by the shorter period of i.v. morphine requirement, although in Italian liras and then converted into US$ (1 US$ = approximately 1550 liras at the exchange rate of the difference was not statistically significant. Fever was also quite common, occurring in 13 and 19 patients of Gthe time the study was carried out). The daily cost of antibiotic therapy and parenteral nutrition was estimated at CSF and control groups, respectively. Again, G-CSF administration was associated with fewer days of fever and US$86 and 90, respectively; daily cost for laboratory test monitoring resulted in US$54. At our Hospital, the cost of non-prophylactic i.v. antibiotic therapy (see Table 3 ). In the absence of severe infectious complications, no differences hospitalization amounts to about US$515 per day for the in the incidence of foci of infections or positive cultures could be documented in the two groups. Patients were discharged from the BMT Unit when their ANC was Ͼ500/l for 2 consecutive days, in the absence of fever or any active infection. The median duration of hospital stay was thus significantly shorter in the G-CSF group than in the control group.
Analysis of treatment costs for the post-graft period
Both patient groups were identically treated with regard to costs between the two groups were assessed only for the post-graft period. As shown in Table 4 , G-CSF cost was balanced by reduced requests for supportive care therapy; CD34 + cells/kg. This rules out the possibility that G-CSF efficacy depends on suboptimal quantities of hemopoietic this contributed to an overall reduction in treatment costs for the G-CSF group compared to the control group. Also, progenitors in the grafted inoculum. Growth factor enhancement on neutrophil recovery has hospitalization costs were reduced in the G-CSF group. Thus, the estimated average treatment cost for post-graft already been reported in previous studies. [8] [9] [10] [11] 13, 15 In our analysis, this enhancing activity could be reproduced in the recovery was US$3627 lower in the G-CSF group compared to the control group, implying a cost reduction of presence of optimal conditions such as (1) most patients at disease onset; (2) use of the same mobilization procedures; approximately 16% (see Table 4 ).
(3) identical conditioning regimen; (4) autograft performed with large quantities of PBPC without additional BM cells. Neutrophil recovery was consistently faster in every patient Discussion receiving G-CSF than it was in controls, as clearly shown in Figure 1 . Furthermore, both extent and duration of proIn this study, the efficacy of G-CSF following PBPC autograft was evaluated by comparing two sequential groups of found neutropenia, ie ANC Ͻ 100/l, were reduced with G-CSF. Finally, we found that stimulating neutrophil recovpatients with lymphoid malignancies, autografted with or without G-CSF support. The study was not randomized; ery does not preclude a stable engraftment of all hemopoietic lineages, as proved by normal cell blood counts however, there were no major differences in clinical presentation between the two groups. In addition, most patients recorded at 6 months following autograft. A trend towards a faster platelet recovery was also were enrolled at diagnosis and few others were at first relapse; this minimizes the potential influence of heavy preobserved in G-CSF-treated patients, although the difference was not statistically significant compared to controls. Simitreatment on the post-graft outcome. Finally, all patients were evaluated during a relatively short period of time, less lar behavior can be observed in some previously reported series. 9,13,15 Various hypotheses might explain the mild than 3 years, and no critical changes in patient management had been introduced since the study was started. Therefore though consistent efficacy of G-CSF on platelet recovery. One could speculate that G-CSF has a role on the whole no clinical or therapeutic variables other than G-CSF administration can explain the differences observed in hemhemopoietic system, including megakaryocytopoiesis, by its direct or indirect activity on the early stem cells, as sugatological recovery and in overall treatment tolerability between the two patient groups.
gested previously by in vitro observations. 38,39 This stimulatory activity is more clearly detectable in the PBPC autoReinfusion of large numbers of progenitor cells is responsible for the rapid engraftment following submyegraft setting, due to the large numbers of early stem cells that are grafted along with committed progenitors. 30, 32, 33 loablative regimens. [16] [17] [18] [19] 32, 33 A direct correlation between the number of reinfused progenitors and speed of hematolAlternatively, the less pronounced thrombocytopenia might be correlated with better clinical conditions, resulting from ogic recovery is well known and values ranging from 2 to 5 × 10 6 CD34 + cells/kg have been proposed as the minia shorter neutropenic duration; this could favor platelet survival with improved efficacy of platelet transfusions and mum PBPC dose required to guarantee rapid and stable engraftment. 21, [33] [34] [35] [36] In our HDS programs, a dose as high overall milder thrombocytopenia. There is no general agreement about better autotransplant as 8 × 10 6 CD34 + cells/kg is considered as the ideal value for a safe PBPC transplant. 37 Also in the present study, the tolerability as a consequence of growth factor-induced shorter neutropenia. In particular, Spitzer et al 10 found no median value of autografted progenitors was high in both groups: only two patients were autografted with less than clear benefits of GM-CSF administration. However, in their study, there was a marked heterogeneity in terms of both 8 × 10 6 CD34 + cells/kg, and none with less than 5 × 10 6 patient characteristics and treatment modalities; nevertheless, they also reported that patients who received GM-CSF Table 4 Average treatment costs for the post-graft recovery period had a shorter hospital stay than those who did not, suggesting a certain clinical benefit. In addition, GM-CSF side- around US$1300. Thus, this study may provide further 
